169 related articles for article (PubMed ID: 19405552)
1. Fesoterodine.
McKeage K; Keating GM
Drugs; 2009; 69(6):731-8. PubMed ID: 19405552
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
3. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
4. Fesoterodine fumarate.
Gomelsky A; Dmochowski RR
Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
6. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
7. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
8. Fesoterodine: a new agent for treating overactive bladder.
Ellsworth P; Berriman SJ; Brodsky M
Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
Sand PK; Heesakkers J; Kraus SR; Carlsson M; Guan Z; Berriman S
Drugs Aging; 2012 Feb; 29(2):119-31. PubMed ID: 22276958
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of fesoterodine in women with overactive bladder.
Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
[TBL] [Abstract][Full Text] [Related]
15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
[TBL] [Abstract][Full Text] [Related]
17. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
18. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
[TBL] [Abstract][Full Text] [Related]
19. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
[TBL] [Abstract][Full Text] [Related]
20. Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.
Dell'Utri C; Digesu GA; Bhide A; Khullar V
Int Urogynecol J; 2012 Oct; 23(10):1337-44. PubMed ID: 22411206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
